Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal

Indaptus Therapeutics, Inc.

2024-Q3 EPS reported -$1.23

Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).
Cash and equivalents $7.4M at Sep 30, 2024, down from $13.4M at Dec 31, 2023; cash runway into Q1 2025.
Clinical supply agreement with BeiGene to combine Decoy20 with tislelizumab (anti-PD-1) for advanced solid tumors.
Phase 1 trial of Decoy20 now allows unrestricted enrollment for weekly dosing at lower dose; well tolerated.
R&D expenses decreased to $1.5M in Q3 2024 from $2.2M YoY; completed $3M registered direct offering in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.